インターロイキン6 IL6阻害剤の世界市場レポート 2025年

インターロイキン6 IL6阻害剤市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.6％で539億6,000万米ドルに成長します。予測期間の成長は、ヘルスケアシステムのインフラ、規制・政策の変更、資金調達と投資、医薬品パイプラインの開発、医療界の支持などに起因すると考えられます。予測期間における主な動向としては、高度な分子工学、新規生物製剤の開発、新規治療領域の開拓、ゲノム・プロテオームデータとの統合、ドラッグデリバリーシステムの強化などが挙げられます。

神経疾患の有病率の上昇は、今後数年間におけるインターロイキン-6（IL-6）阻害剤市場の成長を牽引すると予測されます。神経疾患には、脳、脊髄、末梢神経を含む神経系に影響を及ぼす幅広い疾患が含まれます。これらの疾患の発生率が増加しているのは、高齢化、診断技術の向上、意識の高まり、ストレス、座りがちな生活、食生活の乱れといったライフスタイルの要素などが原因となっています。IL-6阻害剤は、脳における炎症を緩和し、免疫系の過活動を抑制することにより、神経疾患の管理において重要な役割を果たすものであり、多発性硬化症やアルツハイマー病などの症状を緩和し、疾患の進行を遅らせることができます。例えば、2023年3月に国立医学図書館が発表した報告書によると、2023年には65歳以上のアメリカ人のうち約670万人がアルツハイマー型認知症を患い、その数は2060年までに1,380万人に増加すると予測されています。その結果、神経疾患の有病率の増加がインターロイキン6阻害剤市場を大きく牽引しています。

インターロイキン-6（IL-6）阻害剤市場の主要企業は、治療の選択肢を広げ、患者の転帰を改善するため、初めて承認されたトシリズマブのバイオシミラーなど、先進的なソリューションの開発に注力しています。初めて承認されたトシリズマブのバイオシミラー医薬品は、関節リウマチや若年性関節炎などの炎症性疾患の治療に使用されるIL-6受容体阻害剤であるアクテムラの高度類似品です。例えば、2023年11月には、ドイツを拠点とするヘルスケア企業であるフレゼニウス・カビが、様々な炎症性疾患や免疫介在性疾患の治療薬であるタイエンを発売しました。この治療薬は、皮下投与（プレフィルドシリンジやオートインジェクターによる）や静脈内投与（バイアルによる）などの柔軟な投与オプションを備えており、医療従事者は個々の患者のニーズに合わせて治療を行うことができます。タイエンは、現在トシリズマブの投与を受けている欧州の患者にとって、アクセスしやすく、手頃な価格で、高品質かつ安全な代替薬となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界インターロイキン6 IL6阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のインターロイキン6 IL6阻害剤市場：成長率分析
• 世界のインターロイキン6 IL6阻害剤市場の実績：規模と成長, 2019-2024
• 世界のインターロイキン6 IL6阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界インターロイキン6 IL6阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のインターロイキン6 IL6阻害剤市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トシリズマブ
• シルツキシマブ
• シルヴァント
• 世界のインターロイキン6 IL6阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）
• 皮下（SC）
• その他の投与経路
• 世界のインターロイキン6 IL6阻害剤市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 腫瘍学
• 全身性若年性特発性関節炎
• 巨細胞性動脈炎
• COVID-19関連のサイトカインストーム
• その他の適応症
• 世界のインターロイキン6 IL6阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 病院薬局
• 専門薬局
• オンライン薬局
• その他の流通チャネル
• 世界のインターロイキン6 IL6阻害剤市場トシリズマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用トシリズマブ
• 静脈内トシリズマブ
• 皮下トシリズマブ
• 世界のインターロイキン6 IL6阻害剤市場シルツキシマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用シルツキシマブ
• シルツキシマブ単剤療法
• シルツキシマブ併用療法
• 世界のインターロイキン6 IL6阻害剤市場、シルヴァントのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射用シルヴァント
• 多中心性キャッスルマン病に対するシルヴァント
• シルヴァント併用療法

第7章 地域別・国別分析

• 世界のインターロイキン6 IL6阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のインターロイキン6 IL6阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インターロイキン6 IL6阻害剤市場：競合情勢
• インターロイキン6 IL6阻害剤市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Galapagos N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Amgen Inc.
• Merck KGaA
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Chugai Pharmaceutical Co Ltd
• Celltrion Inc.
• Dynavax Technologies Corporation
• Argenx SE
• Aclaris Therapeutics Inc.
• Genentech Inc.
• Evelo Biosciences Inc.
• BPS Bioscience Inc.
• Tiziana Life Sciences PLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インターロイキン6 IL6阻害剤市場2029：新たな機会を提供する国
• インターロイキン6 IL6阻害剤市場2029：新たな機会を提供するセグメント
• インターロイキン6 IL6阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Interleukin-6 (IL-6) inhibitors are medications that block the activity of IL-6, a cytokine involved in inflammation and immune responses. These inhibitors are utilized to treat conditions such as rheumatoid arthritis, certain cancers, and other inflammatory diseases. By targeting IL-6, they help reduce inflammation and modulate the immune system.

The primary product types of IL-6 inhibitors include tocilizumab, siltuximab, and sylvan. Tocilizumab is a monoclonal antibody that blocks the IL-6 receptor and is used to treat inflammatory conditions such as rheumatoid arthritis and cytokine release syndrome. It can be administered through various routes, including intravenous (IV), subcutaneous (SC), and others. The indications for IL-6 inhibitors encompass rheumatoid arthritis, oncology, systemic juvenile idiopathic arthritis, giant cell arteritis, and COVID-19-related cytokine storm, among others. Distribution channels include retail pharmacies, hospital pharmacies, specialty pharmacies, online pharmacies, and more.

The interleukin6 (IL-6) inhibitor market research report is one of a series of new reports from The Business Research Company that provides interleukin6 (IL-6) inhibitor market statistics, including the interleukin6 (IL-6) inhibitor industry's global market size, regional shares, competitors with an interleukin6 (IL-6) inhibitor market share, detailed interleukin6 (IL-6) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin6 (IL-6) inhibitor industry. This interleukin6 (IL-6) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interleukin6 il6 inhibitor market size has grown rapidly in recent years. It will grow from $32.57 billion in 2024 to $36.1 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing clinical trials and research, increasing awareness, increasing patient advocacy and demand, increasing public awareness and education, and increasing the emergence of biosimilars.

The interleukin6 il6 inhibitor market size is expected to see rapid growth in the next few years. It will grow to $53.96 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to healthcare system infrastructure, regulatory and policy changes, funding and investment, pharmaceutical pipeline developments, and medical community endorsement. Major trends in the forecast period include advanced molecular engineering, development of novel biologics, exploration of new therapeutic areas, integration with genomic and proteomic data, and enhanced drug delivery systems.

The rising prevalence of neurological disorders is projected to drive the growth of the interleukin-6 (IL-6) inhibitor market in the coming years. Neurological disorders encompass a broad spectrum of conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. The increasing incidence of these disorders is attributed to factors such as an aging population, improved diagnostic techniques, heightened awareness, and lifestyle elements such as stress, sedentary behavior, and poor diet. IL-6 inhibitors play a critical role in managing neurological disorders by mitigating inflammation and reducing immune system overactivity in the brain, which can alleviate symptoms and slow disease progression in conditions such as multiple sclerosis and Alzheimer's disease. For example, a report from the National Library of Medicine in March 2023 estimated that approximately 6.7 million Americans aged 65 and older would be living with Alzheimer's dementia in 2023, a number projected to rise to 13.8 million by 2060. Consequently, the growing prevalence of neurological disorders is significantly driving the interleukin-6 inhibitor market.

Key players in the interleukin-6 (IL-6) inhibitor market are focused on developing advanced solutions, such as the first approved tocilizumab biosimilar, to broaden treatment options and enhance patient outcomes. The first approved tocilizumab biosimilar is a highly similar version of the original Actemra, which is an IL-6 receptor inhibitor used to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, a treatment for various inflammatory and immune-mediated conditions. This medication offers flexible administration options, including subcutaneous (via prefilled syringes and autoinjectors) and intravenous (via vials) formulations, allowing healthcare providers to tailor treatment to individual patient needs. Tyenne presents an accessible, affordable, high-quality, and safe alternative for European patients currently receiving tocilizumab.

In March 2022, Recordati Industria Chimica e Farmaceutica S.p.A., an Italy-based pharmaceutical company, acquired EUSA Pharma (UK) Ltd. for an undisclosed amount. This acquisition aims to broaden Recordati's portfolio in the rare disease segment, enhance its therapeutic focus on rare and niche oncology diseases, and improve its capacity to deliver innovative treatments that address significant unmet medical needs. EUSA Pharma (UK) Ltd. is a UK-based pharmaceutical company specializing in rare and oncology products, including SYLVANT (siltuximab).

Major companies operating in the interleukin6 (IL-6) inhibitor market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Sanofi S.A., Galapagos N.V., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogene Inc., Chugai Pharmaceutical Co Ltd., Celltrion Inc., Dynavax Technologies Corporation, Argenx SE, Aclaris Therapeutics Inc., Genentech Inc., Evelo Biosciences Inc., BPS Bioscience Inc., Tiziana Life Sciences PLC

Asia-Pacific was the largest region in the interleukin6 (IL-6) inhibitor market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin6 il6 inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the interleukin6 il6 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interleukin6 (IL-6) inhibitor market consists of sales of clazakizumab, sirukumab, olokizumab, brezulimab, and mavrilimumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

InterLeukin6 IL6 Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on interleukin6 il6 inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for interleukin6 il6 inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The interleukin6 il6 inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Tocilizumab; Siltuximab; Sylvant
• 2) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Other Route Of Administration
• 3) By Indication: Rheumatoid Arthritis; Oncology; Systemic Juvenile Idiopathic Arthritis; Giant Cell Arteritis; COVID-19-Related Cytokine Storm; Other Indications
• 4) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Specialty Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Tocilizumab: Injectable Tocilizumab; Intravenous Tocilizumab; Subcutaneous Tocilizumab
• 2) By Siltuximab: Injectable Siltuximab; Monotherapy Siltuximab; Combination Therapy Siltuximab
• 3) By Sylvant: Injectable Sylvant; Sylvant For Multicentric Castleman Disease; Sylvant In Combination Treatments
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd; Sanofi S.A.; Galapagos N.V.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. InterLeukin6 IL6 Inhibitor Market Characteristics

3. InterLeukin6 IL6 Inhibitor Market Trends And Strategies

4. InterLeukin6 IL6 Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global InterLeukin6 IL6 Inhibitor Growth Analysis And Strategic Analysis Framework

• 5.1. Global InterLeukin6 IL6 Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global InterLeukin6 IL6 Inhibitor Market Growth Rate Analysis
• 5.4. Global InterLeukin6 IL6 Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global InterLeukin6 IL6 Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global InterLeukin6 IL6 Inhibitor Total Addressable Market (TAM)

6. InterLeukin6 IL6 Inhibitor Market Segmentation

• 6.1. Global InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tocilizumab
• Siltuximab
• Sylvant
• 6.2. Global InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV)
• Subcutaneous (SC)
• Other Route Of Administration
• 6.3. Global InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Oncology
• Systemic Juvenile Idiopathic Arthritis
• Giant Cell Arteritis
• COVID-19-Related Cytokine Storm
• Other Indications
• 6.4. Global InterLeukin6 IL6 Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global InterLeukin6 IL6 Inhibitor Market, Sub-Segmentation Of Tocilizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Tocilizumab
• Intravenous Tocilizumab
• Subcutaneous Tocilizumab
• 6.6. Global InterLeukin6 IL6 Inhibitor Market, Sub-Segmentation Of Siltuximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Siltuximab
• Monotherapy Siltuximab
• Combination Therapy Siltuximab
• 6.7. Global InterLeukin6 IL6 Inhibitor Market, Sub-Segmentation Of Sylvant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Sylvant
• Sylvant For Multicentric Castleman Disease
• Sylvant In Combination Treatments

7. InterLeukin6 IL6 Inhibitor Market Regional And Country Analysis

• 7.1. Global InterLeukin6 IL6 Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global InterLeukin6 IL6 Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific InterLeukin6 IL6 Inhibitor Market

• 8.1. Asia-Pacific InterLeukin6 IL6 Inhibitor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China InterLeukin6 IL6 Inhibitor Market

• 9.1. China InterLeukin6 IL6 Inhibitor Market Overview
• 9.2. China InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India InterLeukin6 IL6 Inhibitor Market

• 10.1. India InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan InterLeukin6 IL6 Inhibitor Market

• 11.1. Japan InterLeukin6 IL6 Inhibitor Market Overview
• 11.2. Japan InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia InterLeukin6 IL6 Inhibitor Market

• 12.1. Australia InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia InterLeukin6 IL6 Inhibitor Market

• 13.1. Indonesia InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea InterLeukin6 IL6 Inhibitor Market

• 14.1. South Korea InterLeukin6 IL6 Inhibitor Market Overview
• 14.2. South Korea InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe InterLeukin6 IL6 Inhibitor Market

• 15.1. Western Europe InterLeukin6 IL6 Inhibitor Market Overview
• 15.2. Western Europe InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK InterLeukin6 IL6 Inhibitor Market

• 16.1. UK InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany InterLeukin6 IL6 Inhibitor Market

• 17.1. Germany InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France InterLeukin6 IL6 Inhibitor Market

• 18.1. France InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy InterLeukin6 IL6 Inhibitor Market

• 19.1. Italy InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain InterLeukin6 IL6 Inhibitor Market

• 20.1. Spain InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe InterLeukin6 IL6 Inhibitor Market

• 21.1. Eastern Europe InterLeukin6 IL6 Inhibitor Market Overview
• 21.2. Eastern Europe InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia InterLeukin6 IL6 Inhibitor Market

• 22.1. Russia InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America InterLeukin6 IL6 Inhibitor Market

• 23.1. North America InterLeukin6 IL6 Inhibitor Market Overview
• 23.2. North America InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA InterLeukin6 IL6 Inhibitor Market

• 24.1. USA InterLeukin6 IL6 Inhibitor Market Overview
• 24.2. USA InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada InterLeukin6 IL6 Inhibitor Market

• 25.1. Canada InterLeukin6 IL6 Inhibitor Market Overview
• 25.2. Canada InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America InterLeukin6 IL6 Inhibitor Market

• 26.1. South America InterLeukin6 IL6 Inhibitor Market Overview
• 26.2. South America InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil InterLeukin6 IL6 Inhibitor Market

• 27.1. Brazil InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East InterLeukin6 IL6 Inhibitor Market

• 28.1. Middle East InterLeukin6 IL6 Inhibitor Market Overview
• 28.2. Middle East InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa InterLeukin6 IL6 Inhibitor Market

• 29.1. Africa InterLeukin6 IL6 Inhibitor Market Overview
• 29.2. Africa InterLeukin6 IL6 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa InterLeukin6 IL6 Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa InterLeukin6 IL6 Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. InterLeukin6 IL6 Inhibitor Market Competitive Landscape And Company Profiles

• 30.1. InterLeukin6 IL6 Inhibitor Market Competitive Landscape
• 30.2. InterLeukin6 IL6 Inhibitor Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Galapagos N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. InterLeukin6 IL6 Inhibitor Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Amgen Inc.
• 31.3. Merck KGaA
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Astellas Pharma Inc.
• 31.6. Biogen Inc.
• 31.7. Chugai Pharmaceutical Co Ltd
• 31.8. Celltrion Inc.
• 31.9. Dynavax Technologies Corporation
• 31.10. Argenx SE
• 31.11. Aclaris Therapeutics Inc.
• 31.12. Genentech Inc.
• 31.13. Evelo Biosciences Inc.
• 31.14. BPS Bioscience Inc.
• 31.15. Tiziana Life Sciences PLC

32. Global InterLeukin6 IL6 Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The InterLeukin6 IL6 Inhibitor Market

34. Recent Developments In The InterLeukin6 IL6 Inhibitor Market

35. InterLeukin6 IL6 Inhibitor Market High Potential Countries, Segments and Strategies

• 35.1 InterLeukin6 IL6 Inhibitor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 InterLeukin6 IL6 Inhibitor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 InterLeukin6 IL6 Inhibitor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer